Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2002-01-25
- Employees
- 1K
- Market Cap
- -
- Website
- https://www.3s-guojian.com
Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-03-22
- Target Recruit Count
- 104
- Registration Number
- NCT06324812
Efficacy and Safety Study of 610 in Patients With Severe Asthma
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Target Recruit Count
- 480
- Registration Number
- NCT06323213
An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-03-08
- Target Recruit Count
- 750
- Registration Number
- NCT06299982
A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-08-05
- Target Recruit Count
- 157
- Registration Number
- NCT06270225
- Locations
- 🇨🇳
Shanghai Huashan Hospital Fudan University-Rheumatology, Shanghai, Shanghai, China
A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-10-23
- Target Recruit Count
- 250
- Registration Number
- NCT06242652
- Locations
- 🇨🇳
Site 01, Beijing, Beijing, China
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Target Recruit Count
- 180
- Registration Number
- NCT06222671
- Locations
- 🇨🇳
Site 02, Zhengzhou, Henan, China
🇨🇳Site 04, Nanjing, Jiangsu, China
🇨🇳Site 03, Beijing, Beijing, China
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-02-01
- Target Recruit Count
- 510
- Registration Number
- NCT06173284
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua, Zhejiang, China
A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2023-12-14
- Target Recruit Count
- 500
- Registration Number
- NCT06169891
Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-02-01
- Target Recruit Count
- 150
- Registration Number
- NCT06099652
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
The MAD Study of SSGJ-613 in Healthy Subjects
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Target Recruit Count
- 36
- Registration Number
- NCT05966701
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath